| 000 | 01857cam a2200253 4500 | ||
|---|---|---|---|
| 001 | 0826172148 | ||
| 008 | 200608t2019 xxu||||| |||| 00| 0 eng d | ||
| 020 | _a0826172148 | ||
| 020 | _a9780826172143 | ||
| 100 | _aErnstoff, Marc (ed) | ||
| 245 | 0 | _aSITC's Guide to Managing Immunotherapy Toxicity | |
| 260 |
_aUnited States : _bSpringer, _c2019 |
||
| 505 | _aOverview of Anti-CLA-4 agents - ipilimunab and tremelimumab; Overview of PD-1 and PD-L1 inhibitors; Indication and toxicities of immune checkpoint inhibitor combinations; General principles of immune-related toxicities; Dermatologic toxicities - rash, mucosal irritation, and pruritus; Muskuloskeletal and rheumatologic toxicities; Immune-related gastrointestinal toxicities; Pneumotoxicity associated with immune checkpoint blockades; Immune-related endocrinopathies associated with immune checkpoint inhibitors; Neurologic adverse events and neurologic complications; Cardiovascular toxicities related to immune checkpoint inhibitors; Renal toxicities associated with immune checkpoint inhibitors; Haematologic toxicities of apparent immune-related origins; Ocular toxicities caused by immune dysregulation; Safety and regulation of immune checkpoint inhibitors in special patient populations; Cancer-related fatigue in patients of immune checkpoint inhibitor therapy; Cost-effectiveness and financial toxicity of new cancer therapies | ||
| 520 | _aSITC's Guide to Managing Immunotherapy Toxicity is a practical reference to managing side effects associated with FDA-approved cancer immunotherapy drugs | ||
| 650 |
_aImmunotherapy _96577 |
||
| 650 |
_aOncology _913364 |
||
| 690 |
_aImmunotherapy _96577 |
||
| 690 |
_aOncology _913364 |
||
| 700 | _aPuzanov, Igor (ed) | ||
| 700 | _aRobert, Caroline (ed) | ||
| 700 | _aDiab, Adi (ed) | ||
| 700 | _aHersey, Peter (ed) | ||
| 999 |
_c42295 _d42295 |
||